HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Parse Biosciences introduces workflow for immune repertoire and transcriptome analysis: Seattle Saturday, January 24, 2026, 15:00 Hrs [IST] Parse Biosciences, the leading provider ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

According to Nova One Advisor, the global next-generation sequencing market size is calculated at USD 17.37 billion in 2026 ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

AgriPrep Library Prep Kit is designed to facilitate adoption of low-pass sequencing & SKIM-sequencing of plant and animal genomes at a fraction of the cost of WGS. AgriPrep is a tagmentation-based ...